255 related articles for article (PubMed ID: 26494936)
1. Helicobacter pylori Antibody Titer and Gastric Cancer Screening.
Kishikawa H; Kimura K; Takarabe S; Kaida S; Nishida J
Dis Markers; 2015; 2015():156719. PubMed ID: 26494936
[TBL] [Abstract][Full Text] [Related]
2. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
3. Gastric Cancer Screening by Combined Determination of Serum
Chen XZ; Huang CZ; Hu WX; Liu Y; Yao XQ
Chin Med J (Engl); 2018 May; 131(10):1232-1239. PubMed ID: 29722342
[TBL] [Abstract][Full Text] [Related]
4. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
[TBL] [Abstract][Full Text] [Related]
5. High-Negative Anti-
Inoue M; Sawada N; Goto A; Shimazu T; Yamaji T; Iwasaki M; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):420-426. PubMed ID: 31826914
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".
Miki K
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(7):405-14. PubMed ID: 21785258
[TBL] [Abstract][Full Text] [Related]
7. Analysis of ABC (D) stratification for screening patients with gastric cancer.
Kudo T; Kakizaki S; Sohara N; Onozato Y; Okamura S; Inui Y; Mori M
World J Gastroenterol; 2011 Nov; 17(43):4793-8. PubMed ID: 22147980
[TBL] [Abstract][Full Text] [Related]
8. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
[TBL] [Abstract][Full Text] [Related]
9. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.
Cao Q; Ran ZH; Xiao SD
J Dig Dis; 2007 Feb; 8(1):15-22. PubMed ID: 17261130
[TBL] [Abstract][Full Text] [Related]
10. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
11. Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer.
Kishino T; Oyama T; Tomori A; Takahashi A; Shinohara T
Intern Med; 2020 Jun; 59(12):1473-1480. PubMed ID: 32188803
[TBL] [Abstract][Full Text] [Related]
12. Serum Helicobacter pylori CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan.
Shiota S; Murakami K; Okimoto T; Kodama M; Yamaoka Y
J Gastroenterol Hepatol; 2014 Jan; 29(1):67-73. PubMed ID: 24033876
[TBL] [Abstract][Full Text] [Related]
13. Identification of Helicobacter pylori-related gastric cancer risk using serological gastritis markers and endoscopic findings: a large-scale retrospective cohort study.
Nagasaki N; Ito M; Boda T; Kotachi T; Takigawa H; Oka S; Tanaka S
BMC Gastroenterol; 2022 Jun; 22(1):299. PubMed ID: 35725370
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K; Oka M; Yoshimura N; Mukoubayashi C; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Yamamichi N; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2008 Aug; 123(4):917-26. PubMed ID: 18508314
[TBL] [Abstract][Full Text] [Related]
15. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
16. Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status.
Kishikawa H; Nishida J; Ichikawa H; Kaida S; Takarabe S; Matsukubo T; Miura S; Morishita T; Hibi T
Helicobacter; 2011 Dec; 16(6):427-33. PubMed ID: 22059393
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-
Toyoshima O; Nishizawa T; Sakitani K; Yamakawa T; Takahashi Y; Yamamichi N; Hata K; Seto Y; Koike K; Watanabe H; Suzuki H
World J Gastroenterol; 2018 Sep; 24(35):4061-4068. PubMed ID: 30254410
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Gastric Neoplasia in Cases Negative for Helicobacter pylori Antibody and with Normal Pepsinogen.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Nishida J
Anticancer Res; 2015 Dec; 35(12):6765-71. PubMed ID: 26637894
[TBL] [Abstract][Full Text] [Related]
19. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer.
Aromaa A; Kosunen TU; Knekt P; Maatela J; Teppo L; Heinonen OP; Härkönen M; Hakama MK
Am J Epidemiol; 1996 Jul; 144(2):142-9. PubMed ID: 8678045
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
